DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/hwz97s/antiobesity) has announced the addition of the "Anti-Obesity Drugs - Global Strategic Business Report" report to their offering.
This report analyzes the worldwide markets for Anti-Obesity Drugs in US$ Million. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World.
Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs.
The report profiles 33 companies including many key and niche players such as:
- Arena Pharmaceuticals, Inc.
- GlaxoSmithKline Plc
- Novo Nordisk
- Orexigen Therapeutics, Inc.
- Rhythm Pharmaceuticals
Key Topics Covered:
I. Introduction, Methodology & Product Definitions
II. Executive Summary
1. Industry Overview
2. Competitive Scenario
3. Market Trends, Drivers And Challenges
4. Select Pipeline Drug Candidates
5. Select Scientific Breakthroughs
6. Obesity An Introduction
7. Obesity Treatment
8. Anti-Obesity Drugs An Insight
9. Recent Industry Activity
10. Focus On Select Players
11. Global Market Perspective
1. The United States
6. Latin America
7. Rest Of World
IV. Competitive Landscape
Total Companies Profiled: 33 (including Divisions/Subsidiaries 34)
- The United States (14)
- Japan (4)
- Europe (8)
- The United Kingdom (3)
- Rest of Europe (5)
- Asia-Pacific (Excluding Japan) (8)
For more information visit http://www.researchandmarkets.com/research/hwz97s/antiobesity